Item 2.02. Results of Operations and Financial Condition
On January 5, 2023, Marinus Pharmaceuticals, Inc. (the "Company") issued a press
release announcing its preliminary net product revenue for the fourth quarter
and the year ended December 31, 2022 and certain other information (the "Press
Release"). The amounts included in the Press Release are preliminary, have not
been audited and are subject to change upon completion of the Company's audited
financial statements for the year ended December 31, 2022. Additional
information and disclosures would be required for a more complete understanding
of the Company's financial position and results of operations as of December 31,
2022. A copy of the Press Release is filed herewith as Exhibit 99.1 to this
Current Report on Form 8-K and is incorporated by reference herein.
Item 8.01. Other Events.
On January 5, 2023, the Company issued the Press Release, a copy of which is
filed herewith as Exhibit 99.1 to this Current Report on Form 8-K and is
incorporated by reference herein.
Item 9.01. Financial Statements and Exhibits.
Exhibit
No. Description
99.1 Press Release, dated January 5, 2023, of Marinus Pharmaceuticals,
Inc.
104 The cover page from this Current Report on Form 8-K, formatted in
Inline XBRL.
© Edgar Online, source Glimpses